Quoin Pharmaceuticals. Ltd Sponsored ADR QNRX 深 沪
已收盘 11-13 16:00:00 美东时间
3.70
-0.050
-1.33%
华盛通- 最 高3.9899
- 今 开3.68
- 成交量 1.60万股
- 最 低 3.55
- 昨 收 3.75
- 总市值 1777.54万
- 52周最高 23.50
- 市盈率 静 --
- 换手率 0.33%
- 52周最低 3.25
- 委 比 -98.83%
- 总股本 480.42万
- 历史最高 1417500.00
- 量 比 1.77
- 振 幅 11.73%
- 历史最低 3.25
- 每 手 1
- 风险率 3.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Quoin Pharmaceuticals Q3 EPS $(0.97) Beats $(1.52) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.52) by 36.18 percent. This is a 85.54 percent increase over losses of $(6.71) per share from the same period last year.
11-05 21:31
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of marketing authorization in the European Union – Designation Repre...
10-14 18:31
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue
Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NAS...
10-06 18:41
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.
09-23 22:23
FDA Grants Rare Pediatric Disease Designation For Quoin Pharma’s Lead Asset, QRX003, For Treatment Of Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Init...
09-08 20:35
Quoin Pharmaceuticals Stock Surges Friday: What's Happening?
Shares of Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) are rallying Friday morning following back-to-back pre-market updates detailing positive clinical trial results and a major institutional financing package. Quoin Pharmaceuticals shares are climbing with conviction. What’s behind QNRX gains? Positiv...
08-28 21:40
Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Shares of Elastic NV (NASDAQ:ESTC) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY27 guidance. Elastic posted quarterly adjusted earnings of 70 cents per share, beating market estimates of 58 cents per share. The co...
08-28 18:31
